New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
09:01 EDTPCYCPharmacyclics downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Pharmacyclics to Sector Perform and reduced its price target to $95 from $110 to reflect upcoming headwinds from ABBVIE and Gilead upcoming filings, slowing new scripts data, Phase III RESONATE data at ASCO might not have the buzz expected and lack of near-term catalysts.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
14:11 EDTPCYCPharmacyclics weakness on safety issues overdone, says Deutsche Bank
Subscribe for More Information
August 18, 2014
16:08 EDTPCYCPharmacyclics names Shawn Cline Tomasello as Chief Commercial Officer
Cline Tomasello is a 30-year industry veteran and former President of the Americas, Hematology and Oncology, for the Celgene Corporation, where she managed over $4B in revenue. Prior to joining Celgene, Cline Tomasello was the National Director of Hematology for Rituxan at Genentech, where she was responsible for over $1.7B in revenue.
August 8, 2014
08:17 EDTPCYCPharmacyclics announces Jesse McGreivy to step down from Chief Medical Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use